Selective estrogen receptor modulation: Concept and consequences in cancer

Cancer Cell

Volumn 5, Issue 3, 2004, Pages 207-213

  Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; PARTIAL AGONIST; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

APOPTOSIS; BLOOD CLOTTING DISORDER; BONE DENSITY; BREAST CANCER; CANCER CELL DESTRUCTION; CELL GROWTH; CELL SURVIVAL; COLON CANCER; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SENSITIVITY; ENDOMETRIUM CANCER; ESTROGEN RELEASE; FRAGILITY FRACTURE; GENE ACTIVATION; GROWTH REGULATION; HIGH RISK POPULATION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; NONHUMAN; ONCOGENE NEU; OSTEOPOROSIS; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SURVIVAL RATE; TARGET ORGAN; UTERUS;

EID: 1642544604     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00059-5     Document Type: Review

References (56)

1. ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer. First results of the ATAC randomized trial Lancet. 359:2002;2131-2139.
2. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engström O., Öhman L., Greene G.L., Gustafsson J.Å., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758.
3. Chisamore M.J., Ahmed Y., Bentrem D.J., Jordan V.C., Tonetti D.A. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha. Clin. Cancer Res. 7:2001;3156-3165.
4. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., Rodabough R.J., Gilligan M.A., Cyr M.G., Thomson C.A.et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The women's health initiative randomized trial JAMA. 289:2003;3243-3253.
5. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., Norton L., Nickelsen T., Bjarnason N.H., Morrow M.et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial Multiple Outcomes of Raloxifene Evaluation. JAMA. 281:1999;2189-2197.
6. EBCTCG Tamoxifen for early breast cancer. An overview of the randomised trials Lancet. 354:1998;1451-1467.
7. Enmark E., Gustafsson J.A. Oestrogen receptors - an overview. J. Intern. Med. 246:1999;133-138.
8. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J.et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA. 282:1999;637-645.
9. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer Inst. 86:1994;527-537.
10. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J.et al. Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 90:1998;1371-1388.
11. Font de Mora J., Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol. 20:2000;5041-5047.
12. Fornander T., Rutqvist L.E., Cedermark B., Glas U., Mattsson A., Silfversward C., Skoog L., Somell A., Theve T., Wilking N., Hjalmar M.-L. Adjuvant tamoxifen in early breast cancer. occurrence of new primary cancers Lancet. 1:1989;117-120.
13. Goss P.E., Ingle J.N., Marino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I.et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349:2003;1-10.
14. Gottardis M.M., Jordan V.C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 47:1987;4020-4024.
15. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., Jordan V.C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48:1988;812-815.
16. Hall J.M., McDonnell D.P., Korach K.S. Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol. Endocrinol. 16:2002;469-486.
17. Jensen E.V., Jordan V.C. The estrogen receptor. a model for molecular medicine. The Dorothy P. Landon AACR Prize for Translational Research Clin. Cancer Res. 9:2003;1980-1989.
18. Jordan V.C. Biochemical pharmacology of antiestrogen action. Pharmacol. Rev. 36:1984;245-276.
19. Jordan V.C. Selective estrogen receptor modulation. a personal perspective Cancer Res. 61:2001;5683-5687.
20. Jordan V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J. Med. Chem. 46:2003;883-908. a.
21. Jordan V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 46:2003;1081-1111. b.
22. Jordan V.C. Tamoxifen. A most unlikely pioneering medicine Nat. Rev. Drug Discov. 2:2003;205-213. c.
23. Jordan V.C., Allen K.E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer. 16:1980;239-251.
24. Jordan V.C., Phelps E., Lindgren J.U. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat. 10:1987;31-35.
25. Khan S., Abdelrahim M., Smamudio I., Safe S. Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17 beta-estradiol in breast cancer cells. Endocrinology. 144:2003;2325-2335.
26. Lauritsen K.J., List H.J., Reiter R., Wellstein A., Riegel A.T. A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene. 21:2002;7147-7155.
27. Lerner L.J., Jordan V.C. The development of antiestrogens for the treatment of breast cancer. Eighth Cain Memorial Award Lecture. Cancer Res. 50:1990;4177-4189.
28. Levin E.R. Bidirectional signaling between the estrogen receptor and the epidermal grwoth factor receptor. Mol. Endocrinol. 17:2003;309-317.
29. Lewis J.S., Cheng D., Jordan V.C. Targeting oestrogen to kill the cancer but not the patient. Br. J. Cancer. 90:2004;822-832.
30. Liu H., Park W.C., Bentrem D.J., McKian K.P., Reyes Ade L., Loweth J.A., Schafer J.M., Zapf J.W., Jordan V.C. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J. Biol. Chem. 277:2002;9189-9198.
31. Liu H., Lee E.S., Gajdos C., Pearce S.T., Chen B., Osipo C., Loweth J., McKian K., De Los Reyes A., Wing L., Jordan V.C. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J. Natl. Cancer Inst. 95:2003;1586-1597.
32. Lonard D.M., Tsai S.Y., O'Malley B.W. Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. Mol. Cell. Biol. 24:2004;14-24.
33. Lonning P.E., Taylor P.D., Anker G., Iddon J., Wie L., Jorgensen L.M., Mella O., Howell A. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res. Treat. 67:2001;111-116.
34. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., Carbone P.P., DeMets D.L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326:1992;852-856.
35. MacGregor Schafer J., Liu H., Bentrem D.J., Zapf J.W., Jordan V.C. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res. 60:2000;5097-5105.
36. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science. 296:2002;1642-1644.
37. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators. cellular and molecular biology Endocr. Rev. 20:1999;321-344.
38. Meyers M.J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor beta potency-selective ligands. Structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues J. Med. Chem. 44:2001;4230-4257.
39. Mosca L., Barrett-Connor E., Wenger N.K., Collins P., Grady D., Kornitzer M., Moscarelli E., Paul S., Wright T.J., Helterbrand J.D., Anderson P.W. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am. J. Cardiol. 88:2001;392-395.
40. MWSC Million Women Study Collaborators). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 362:2003;419-427.
41. Newman S.P., Bates N.P., Vernimmen D., Parker M.G., Hurst H.C. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene. 19:2000;490-497.
42. Osborne C.K., Bardou V., Hopp T.A., Chamness G.C., Hilsenbeck S.G., Fuqua S.A., Wong J., Allred D.C., Clark G., Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC3) and HER2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95:2003;353-361.
43. Osipo C., Gajdos C., Liu H., Chen B., Jordan V.C. Paradoxical action of fulvestrant on estradiol-induced regression of tamoxifen-stimulated breast cancer. J. Natl. Cancer Inst. 95:2003;1597-1607.
44. Pike A.C., Brzozowski A.M., Walton J., Hubbard R.E., Thorsell A., Li Y., Gustafsson J., Carlquist M. Structural insights into the mode of action of a pure antiestrogen. Structure. 9:2001;145-153.
45. Razandi M., Pedram A., Green G.L., Levin E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript. Studies of ER alpha and ER beta expressed in Chinese hamster ovary cells Endocrinology. 13:1999;307-319.
46. Robertson J.F., Osborne C.K., Howell A., Jones S.E., Mauriac L., Ellis M., Kleeberg U.R., Come S.E., Vergote I., Gertler S.et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. A prospective combined analysis of two multicenter trials Cancer. 98:2003;229-238.
47. Shang Y., Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 295:2002;2465-2468.
48. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/co-activator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937.
49. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N. 3rd, Assaf A.R., Jackson R.D.et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. the women's health initiative memory study: A randomized controlled trial JAMA. 289:2003;2651-2662.
50. Song R.X., Mor G., Naftolin F., McPherson R.A., Song J., Zhang Z., Yue W., Wang J., Santen R.J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J. Natl. Cancer Inst. 93:2001;1714-1723.
51. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., Katzenellenbogen B.S., Katzenellenbogen J.A. Pyrazole ligands. Strucutre-affinity/activity relationships and estrogen receptor alpha selective agonists J. Med. Chem. 43:2000;4934-4947.
52. Turner R.T., Wakley G.K., Hannon K.S., Bell N.H. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J. Bone Miner. Res. 2:1987;449-456.
53. Webb P., Lopez G.N., Uht R.M., Kushner P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway. Potential origin for the cell-specific estrogen-like effects of antiestrogens Mol. Endocrinol. 9:1995;443-456.
54. WGWHII Writing Group for the Women's Health Initiative Investigators). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 288:2002;321-333.
55. Wijayaratne A.L., McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 276:2001;35684-35692.
56. Yao K., Lee E.S., Bentrem D.J., England G., Schafer J.I., O'Regan R.M., Jordan V.C. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res. 6:2000;2028-2036.